Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2001

View Archived Issues

Baxter acquires epoetin omega for treating anemia

Angiogene secures further R&D funding

OGS achieves solid progress during first half of 2001

Up to 61% genital wart clearance obtained in phase III trial of Polyphenon E

Fujisawa will market Atrisone in North America

FDA advisory committee decision on Diovan for heart failure indication

Data from three pediatric trials demonstrate efficacy and safety of atomoxetine in ADHD

First approval granted for Spiriva in The Netherlands for treatment of COPD

Lundbeck terminates R&D agreement with Neurochem

Once-daily Adderall XR approved by FDA for ADHD; registration trial discussed at CNS meeting

Reduction in recurrent renal flares and high-dose corticosteroids in LJP-394-treated lupus patients

Phase II clinical trials commence with Transgene's immunotherapeutic for cervical cancer

U.S. phase III efficacy and safety data for Foznol discussed at World Congress of Nephrology

Idec and Mitsubishi extend IDEC-114 collaboration

Ergo Science completes restructuring

Inotek NO-releasing compound shows promise in sheep model of acute lung injury

CeNeS reports progress with pain portfolio during first half of 2001

Adenovirus-mediated IL-10 gene therapy may have potential in the treatment of osteolysis

Potent elastase inhibitors with low toxicity reported by Cermol

Roche prepares series of selective 5-HT2B and/or 5-HT2C agonists

New ketolide antibiotics patented by Pfizer

Anti-H. pylori agents identified by Bayer scientists

Indian group designs peptide antagonists of bombesin and related peptides for cancer Rx

Recent patent covers inhibitors of TGF-beta signaling in development at GSK

XTL Biopharmaceuticals and Biostapro commence antiinfective collaboration

Hybrigenics and Institut Pasteur extend scientific alliance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...